Evidence-based Interpretation of Amyloid-&bgr; PET Results: A Clinician’s Tool

Background: Amyloid-&bgr; positron emission tomography (PET) allows for in vivo detection of fibrillar amyloid plaques, a pathologic hallmark of Alzheimer’s disease (AD). However, amyloid-&bgr; PET interpretation is limited by the imperfect correlation between PET and autopsy, and the fact that it is positive in about 20% to 30% of cognitively normal individuals and non-AD dementias, especially when older or carrying the &egr;4 allele of apolipoprotein E (ApoE4). When facing a positive amyloid PET, clinicians have to evaluate the probability of a pathologic false positive as well as the probability of amyloid positivity being age-related, comorbid to a primary non-AD dementia (clinicopathologic false positive). These probabilities can be calculated to reach an evidence-based interpretation of amyloid-&bgr;. As literature review and calculations cannot be easily performed in the day-to-day clinic, we propose a clinician friendly, evidence-based Bayesian approach to the interpretation of amyloid-&bgr; PET results in the differential diagnosis of patients with cognitive impairment. Methods: We defined AD as a clinicopathologic entity in which amyloid-&bgr; is the primary cause of cognitive impairment. We systematically reviewed the literature to estimate the sensitivity and specificity of amyloid-&bgr; PET against neuropathologic examination. We inferred rates of clinicopathologic false positivity (non-AD dementia with comorbid amyloid) based on age-dependent and ApoE-dependent prevalence of amyloid positivity in normal individuals and AD patients provided in large meta-analyses published by the Amyloid Biomarker Study Group. We calculated positive predictive value (PPV) and negative predictive value (NPV) of amyloid-&bgr; PET, which are presented in a clinician-friendly table. Results: PPV of PET is highest in young ApoE4− patients with high pre-PET probability of AD. In older ApoE4+ patients with low pre-PET probability of AD, positive amyloid-&bgr; PET scans must be interpreted with caution. A negative amyloid-&bgr; PET makes a diagnosis of AD unlikely except in old patients with high pre-PET probability of AD. Conclusion: This evidence-based approach might provide guidance to clinicians and nuclear medicine physicians to interpret amyloid-&bgr; PET results for early and differential diagnosis of patients with progressive cognitive impairment.

[1]  A. Fleisher,et al.  Performance of [18F]flutemetamol amyloid imaging against the neuritic plaque component of CERAD and the current (2012) NIA-AA recommendations for the neuropathologic diagnosis of Alzheimer's disease , 2017, Alzheimer's & dementia.

[2]  Clifford R. Jack,et al.  Tau aggregation influences cognition and hippocampal atrophy in the absence of beta-amyloid: a clinico-imaging-pathological study of primary age-related tauopathy (PART) , 2017, Acta Neuropathologica.

[3]  M. Mesulam,et al.  Case 1-2017. A 70-Year-Old Woman with Gradually Progressive Loss of Language. , 2017, The New England journal of medicine.

[4]  W. Klunk,et al.  Post-mortem histopathology underlying β-amyloid PET imaging following flutemetamol F 18 injection , 2016, Acta neuropathologica communications.

[5]  P. Pasqualetti,et al.  Assessment of the Incremental Diagnostic Value of Florbetapir F 18 Imaging in Patients With Cognitive Impairment: The Incremental Diagnostic Value of Amyloid PET With [18F]-Florbetapir (INDIA-FBP) Study. , 2016, JAMA neurology.

[6]  M. Carrillo,et al.  Research priorities to reduce the global burden of dementia by 2025 , 2016, The Lancet Neurology.

[7]  W. M. van der Flier,et al.  Atrophy, hypometabolism and clinical trajectories in patients with amyloid-negative Alzheimer's disease. , 2016, Brain : a journal of neurology.

[8]  V. Villemagne.  Amyloid imaging: Past, present and future perspectives , 2016, Ageing Research Reviews.

[9]  W. Jagust,et al.  Amyloid negativity in patients with clinically diagnosed Alzheimer disease and MCI , 2016, Neurology.

[10]  M. Carrillo,et al.  Testing and disclosures related to amyloid imaging and Alzheimer's disease: Common questions and fact sheet summary , 2016, Alzheimer's & Dementia.

[11]  A. Fagan,et al.  Suspected non-Alzheimer disease pathophysiology — concept and controversy , 2016, Nature Reviews Neurology.

[12]  Frederik Barkhof,et al.  The behavioural/dysexecutive variant of Alzheimer's disease: clinical, neuroimaging and pathological features. , 2015, Brain : a journal of neurology.

[13]  John Seibyl,et al.  Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: Phase 3 study , 2015, Alzheimer's & Dementia.

[14]  Charles DeCarli,et al.  Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation. , 2015, Brain : a journal of neurology.

[15]  Karen M Rodrigue,et al.  Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. , 2015, JAMA.

[16]  D. Y. Lee,et al.  Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. , 2015, JAMA.

[17]  Clifford R. Jack,et al.  Clinicopathologic and 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer’s disease spectrum , 2015, Brain : a journal of neurology.

[18]  Ranjan Duara,et al.  Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density. , 2015, JAMA neurology.

[19]  G. Rabinovici.  The translational journey of brain β-amyloid imaging: from positron emission tomography to autopsy to clinic. , 2015, JAMA neurology.

[20]  H. Braak,et al.  Are cases with tau pathology occurring in the absence of Aβ deposits part of the AD-related pathological process? , 2014, Acta Neuropathologica.

[21]  Janna H. Neltner,et al.  Primary age-related tauopathy (PART): a common pathology associated with human aging , 2014, Acta Neuropathologica.

[22]  Sandra Weintraub,et al.  Primary progressive aphasia and the evolving neurology of the language network , 2014, Nature Reviews Neurology.

[23]  C. Geula,et al.  Asymmetry and heterogeneity of Alzheimer's and frontotemporal pathology in primary progressive aphasia. , 2014, Brain : a journal of neurology.

[24]  Reisa A. Sperling,et al.  Longitudinal Change in CSF Biomarkers in Autosomal-Dominant Alzheimer’s Disease , 2014, Science Translational Medicine.

[25]  C. Rowe,et al.  Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study , 2013, The Lancet Neurology.

[26]  Gaël Chételat,et al.  Alzheimer disease: Aβ-independent processes—rethinking preclinical AD , 2013, Nature Reviews Neurology.

[27]  Peter Herscovitch,et al.  Appropriate use criteria for amyloid PET: A report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association , 2013, Alzheimer's & Dementia.

[28]  L. Ferrucci,et al.  Correspondence between in vivo 11C-PiB-PET amyloid imaging and postmortem, region-matched assessment of plaques , 2012, Acta Neuropathologica.

[29]  R. Coleman,et al.  Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study , 2012, The Lancet Neurology.

[30]  W. Kukull,et al.  Accuracy of the Clinical Diagnosis of Alzheimer Disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010 , 2012, Journal of neuropathology and experimental neurology.

[31]  J. Schneider,et al.  National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease , 2012, Alzheimer's & Dementia.

[32]  B. Miller,et al.  Classification of primary progressive aphasia and its variants , 2011, Neurology.

[33]  Susan M Resnick,et al.  In vivo fibrillar beta-amyloid detected using [11C]PiB positron emission tomography and neuropathologic assessment in older adults. , 2011, Archives of neurology.

[34]  W. Klunk,et al.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.

[35]  H. Braak,et al.  Phases of Aβ-deposition in the human brain and its relevance for the development of AD , 2002, Neurology.

[36]  N. Risch,et al.  Statement on use of apolipoprotein E testing for Alzheimer disease. American College of Medical Genetics/American Society of Human Genetics Working Group on ApoE and Alzheimer disease. , 1995, JAMA.

[37]  S. M. Sumi,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) , 1991, Neurology.

[38]  C. Jack,et al.  Association of Elevated Amyloid Levels With Cognition and Biomarkers in Cognitively Normal People From the Community. , 2016, JAMA neurology.